The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 26, No. 6, pp. 775-777.
© 1992 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welty, T.
Right arrow Articles by Arazi, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welty, T.
Right arrow Articles by Arazi, R

Research Articles

Loss of seizure control associated with generic substitution of carbamazepine

TE Welty, PR Pickering, BC Hale, and R Arazi

OBJECTIVE: We report two cases of lost seizure control associated with the generic substitution of carbamazepine, review pertinent literature, and discuss the impact of this substitution on patient care. DATA SOURCES: Case studies, abstracts, and research publications identified in MEDLINE and bibliographic review. DATA EXTRACTION: One author reviewed cases supplied by the other authors and abstracted information from published literature sources. DATA SYNTHESIS: The first case describes a 15-year-old boy who received valproic acid and carbamazepine for partial seizures. A change in government program policies caused him to receive generic carbamazepine. This resulted in loss of seizure control and a decrease in his serum carbamazepine concentration from 12.4 to 6.7 micrograms/mL. When his carbamazepine concentration returned to previous levels, seizure control was not reestablished. A second case involves a 21-year-old woman who substituted generic carbamazepine because of financial problems. After being seizure-free for at least five years on phenobarbital and carbamazepine, she experienced seizures related to the product change. Her carbamazepine concentration decreased from 11.8 to 8.5 micrograms/mL; she also became pregnant at that time. Seizure control was not reestablished. At least three other studies do not support these observations, but the tightly controlled conditions in these studies may not have simulated actual clinical practice. CONCLUSIONS: When generic substitution of carbamazepine is required, serum concentrations should be carefully monitored. The extra care required may negate the financial advantages of the substitution.


This article has been cited by other articles:


Home page
 NeurologyHome page
M. J. Berg, R. A. Gross, K. J. Tomaszewski, W. M. Zingaro, and L. S. Haskins
Generic substitution in the treatment of epilepsy: Case evidence of breakthrough seizures
Neurology, August 12, 2008; 71(7): 525 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. E. Murphy
Generic Substitution and Optimal Patient Care
Arch Intern Med, March 8, 1999; 159(5): 429 - 433.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1992 by Harvey Whitney Books Company.